Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116097 | 1.00 | L3MBTL1 (0.46) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4115710 | 0.87 | KDM4E (0.42) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4115712 | 0.87 | KDM4E (0.42) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4111199 | 0.83 | L3MBTL1 (0.41) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4111201 | 0.83 | L3MBTL1 (0.41) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL4123387 | 0.82 | L3MBTL1 (0.43) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL6158724 | 0.75 | TSHR (0.47) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL6158733 | 0.75 | TSHR (0.47) | L3MBTL1GAADHODHMAPTSMN1; SMN2 | |
| SCHEMBL10441874 | 0.75 | KDM4E (0.49) | L3MBTL1GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL4110223 | 0.74 | SMN1; SMN2 (0.42) | L3MBTL1GAADHODHMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258302-B2 | Method for producing benzazepinone | API CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1985615-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | NISCH, GABBR1, GABBR2 | L3MBTL1 4853/4885GAA 682/4885DHODH 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.